Welcome to our dedicated page for Fabrinet SEC filings (Ticker: FN), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Fabrinet (NYSE: FN) SEC filings page brings together the company’s official U.S. Securities and Exchange Commission disclosures, offering investors a structured view of its regulatory record. As a Cayman Islands–incorporated issuer with operations in Thailand, the United States, the People’s Republic of China, and Israel, Fabrinet files detailed reports that explain its financial performance, governance practices, and executive compensation programs.
Through its annual reports on Form 10-K, Fabrinet presents audited financial statements, management’s discussion and analysis, and risk factor disclosures. These documents describe revenue trends across markets such as optical communications, automotive components, industrial lasers, medical devices, and sensors, as well as information on gross margins, operating margins, cash flows, and capital investments in manufacturing facilities and equipment.
Quarterly updates, often furnished via Form 8-K with attached earnings press releases, provide interim financial results and commentary from management. Fabrinet also uses Form 8-K to report material events such as leadership changes, board appointments and retirements, and the adoption of executive incentive plans and equity awards.
The company’s definitive proxy statement on Schedule 14A offers additional insight into corporate governance, including board structure, ESG practices and policies, director and executive compensation, and matters presented for shareholder vote at the Annual General Meeting. It details items such as the election of directors, ratification of the independent auditor, and advisory votes on named executive officer compensation.
On Stock Titan, Fabrinet’s filings are updated in near real time from the SEC’s EDGAR system. AI-powered summaries help explain lengthy documents like the 10-K and proxy statement by highlighting key metrics, governance decisions, compensation structures, and risk discussions. Investors can also review Form 4 and other ownership-related filings to monitor insider transactions and equity awards, using the platform’s tools to quickly understand how these regulatory disclosures relate to Fabrinet’s broader financial and operational profile.
Fabrinet reported the results of its 2025 Annual General Meeting of Shareholders held on December 11, 2025. Shareholders representing 34,035,138 ordinary shares, or about 95% of shares entitled to vote, were present in person or by proxy, indicating very high participation.
Shareholders elected Dr. Homa Bahrami and Caroline Dowling as Class I directors for three-year terms. Each nominee received a strong majority of votes cast. Investors also ratified PricewaterhouseCoopers ABAS Ltd. as Fabrinet’s independent registered public accounting firm for the fiscal year ending June 26, 2026, with substantial support.
In addition, shareholders approved, on an advisory basis, the compensation of Fabrinet’s named executive officers, with a clear majority voting in favor. Overall, all three management-supported proposals received shareholder approval.
Fabrinet director reports small share sale
A Fabrinet (FN) director reported selling 500 ordinary shares on 12/05/2025 at a weighted average price of about $482.11 per share. The transaction is coded as a sale and was conducted directly by the reporting person. After this trade, the director beneficially owns 2,684 Fabrinet ordinary shares.
The price range for the sale was between $482.00 and $482.18 per share, and detailed breakdowns of the individual sale prices within this range are available upon request from the company, the reporting person, or Commission staff.
Fabrinet director Thomas F. Kelly reported recent transactions in the company’s ordinary shares. On 12/04/2025, he sold 2,200 ordinary shares at a weighted average price of $464.142 per share, leaving him with 18,789 shares immediately after that sale. The sale price reflects individual trades executed between $464.12 and $464.24 per share. On 12/05/2025, he reported a gift of 25 shares, after which he beneficially owned 18,764 ordinary shares, all held directly. The transactions were disclosed on a Form 4 filed for a single reporting person in his capacity as a director of Fabrinet.
Fabrinet insider files notice to sell ordinary shares under Rule 144. A holder plans to sell 500 ordinary shares through Citigroup Global Markets on the NYSE, with an aggregate market value of $241,000. The filing states that 35,827,210 ordinary shares were outstanding at the time of the notice, providing context for the planned sale.
The seller previously disposed of additional ordinary shares over the past three months, including 479 shares on 09/05/2025 for gross proceeds of $175,314 and 500 shares on 12/04/2025 for gross proceeds of $236,000. The shares to be sold were originally acquired from Fabrinet as restricted stock that vested on 01/02/2023 in exchange for services rendered.
Fabrinet director Darlene S. Knight reported an open-market sale of company stock. On 12/04/2025, she sold 500 ordinary shares of Fabrinet at a price of $472 per share, according to a Form 4 filing. After this transaction, she beneficially owns 3,184 ordinary shares, held in direct ownership.
Fabrinet director reports small share disposition
A Fabrinet director reported a transaction involving the company’s ordinary shares. On 12/03/2025, the reporting person disposed of 70 ordinary shares at a reported price of $0 under transaction code "G". Following this transaction, the director beneficially owns 14,131 ordinary shares, held directly. No derivative securities transactions were reported.
FN filed a notice of proposed sale of restricted shares under Rule 144. The seller plans to sell 2,200 shares of common stock through Morgan Stanley Smith Barney LLC on or around 12/04/2025 on the NYSE. These shares have an aggregate market value of $1,021,111.30 based on the pricing used in the notice, compared with 35,827,210 shares of the issuer’s stock outstanding. The securities were originally acquired on 01/01/2016 as restricted stock vesting under a registered plan in payment for services rendered.
Fabrinet insider plans modest share sale under Rule 144. A holder intends to sell 500 Ordinary Shares of Fabrinet on the NYSE through Citigroup Global Markets, Inc. The shares have an aggregate market value of $236,000 based on the figures disclosed, with 35,827,210 Ordinary Shares shown as outstanding.
The 500 shares were originally acquired from Fabrinet on 01/02/2023 through restricted stock vesting in exchange for services rendered. The approximate sale date indicated is 12/04/2025 and the planned venue is the NYSE.
Over the past three months, Darlene S. Knight has already sold 479 Ordinary Shares of Fabrinet for gross proceeds of $175,314. By signing the notice, the seller represents they are not aware of any undisclosed material adverse information about Fabrinet’s current or prospective operations.
Fabrinet director reports sale of ordinary shares
A Fabrinet director reported selling 3,500 ordinary shares of the company on 12/01/2025. The transaction was coded as a sale and executed at a weighted average price of $453.747 per share, with individual trade prices ranging from $453.71 to $454.15 per share. After this transaction, the reporting person holds 18,316 Fabrinet ordinary shares, owned directly.
Fabrinet insider files Form 144 to sell ordinary shares. A holder has notified regulators of an intention to sell 3,500 ordinary shares of Fabrinet through Citigroup Global Markets on the NYSE. The planned sale, dated 12/01/2025, is based on an aggregate market value of $1,588,115 as reported in the notice.
The shares were acquired on 12/01/2025 via restricted stock vesting from Fabrinet as consideration for services rendered. Shares outstanding were 35,827,210 at the time of the notice; this is a baseline figure, not the amount being sold. By signing, the seller represents they are not aware of undisclosed material adverse information about Fabrinet’s current or prospective operations.